The past week has been quite fruitful for investors in Northwest Biotherapeutics (OTCMKTS:NWBO) as the company’s stock went on a steady rally and clocked gains of 12% during the period. The company is currently best known for working on the development of DCVax, which is a customized immune therapy meant for tackling solid cancer tumors.
Trading Data
On Friday, NWBO stock increased 1.69% to $0.7840 with 2.82 million shares, compared to volume of 1.56 million shares. The stock moved within a range of $0.7801 – 0.8000 after opening trade at $0.8000.
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA
There has not been any news about the company in the past week but back on August 23, 2022, Northwest announced that its Pedicatric Investigation Plan had been approved by the UK Medicines and Healthcare Products Regulatory Agency. That was a major new development since the approval of the Pediatric Investigation Plan is essential when it comes to getting approval for medicine for the treatment of adults.
The approved Pediatric Investigation Plan is going to consist of as many as two clinical trials. In each of those trials, as many as 24 patients are going to be administered DCVax-L. It should be noted that the primary endpoints of the two clinical trials are overall survival. It goes without saying that the latest development was a major milestone and that may have prompted the steady rally in the stock in the past week.
Technical Data
NWBO stock is trading above the 20-Day and 50-Day Moving averages of $0.70 and $0.69 respectively. However, the stock is trading below the 200-Day moving average of $0.79. The company has a total market capitalization of $813 million.
